Targeting the <scp>ST3</scp> beta‐galactoside alpha‐2,3‐sialyltransferase 1 ( <scp>ST3Gal1</scp> ) as a potential therapeutic strategy to overcome anti‐ <scp>VEGF</scp> resistance in endometrial cancer
ST3Gal1 promotes EC progression by enhancing VEGF-A signaling and EMT via the FAK/paxillin pathway. Its inhibition improves the efficacy of antiangiogenic therapy, supporting ST3Gal1 as a promising therapeutic target to overcome anti-VEGF-A resistance in advanced EC.
Authors
- Chia‐Hao Liu (ORCID: https://orcid.org/0000-0001-8233-5493)
- Chia-Ho Lin (ORCID: https://orcid.org/0000-0002-2690-9648)
- Wei‐Ting Chao (ORCID: https://orcid.org/0000-0001-9234-8853)
- Yu‐Chieh Lee (ORCID: https://orcid.org/0000-0002-1125-5469)
- Shie‐Liang Hsieh (ORCID: https://orcid.org/0000-0001-9415-346X)
- Peng‐Hui Wang (ORCID: https://orcid.org/0000-0002-6048-8541)
- Chiung‐Ru Lai
- Szu‐Ting Yang
- Liang‐Wei Wang
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Health Research Institutes (TW)
- University of Taipei (TW)
- Taipei Veterans General Hospital (TW)
- Genomics Research Center, Academia Sinica (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- International Journal of Gynecology & Obstetrics
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1002/ijgo.70292
- Citations
- 7
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 5.64
Funders
- Female Cancer Foundation
- Taipei Veterans General Hospital